Mayor
Chiang Wan-an of Taipei City said in his speech that Taipei City has the key
advantages required for the development of the biomedical industry, including
high-end talents, innovative R&D capabilities, medical clinical evidence
sites, and abundant and flexible financing. In addition, the Internal Medicine,
Nansoft, Nangang Biotech Clusters, and the Beishi Science Park are connected to
the Taipei Science and Technology Industry Corridor, bringing together domestic
and foreign technology giants. There are more than 10,000 information
and communications companies in the city, fully supporting the cross-domain
development trend of the biomedical and information and communications
industries. There are more than 580 biotech companies in Taipei City,
with annual revenue exceeding NT$ 270 billion, and R&D investment
accounts for nearly 20% of total expenditure . Taipei City's
biomedical industry continues to invest in innovation and development.
Mayor
Chiang said that the Taipei Biotech Park was planned by the city government and
invested and developed by the Shikang Development Company. From the perspective
of land use and building planning, it has been created into a multi-functional
space that provides a one-stop service for research and development, trial
production, and office business. In addition to investing in the construction
of the park, Shikang Company has also precisely targeted the needs of enterprises
and invested NT$ 200 million in shared instruments and equipment for
use by biotech startup teams and enterprises, creating a high-quality
environment for research and development, operations, and industry exchanges in
the Taipei Biotech Park. Currently, there are 36 biomedical companies
stationed in the park, with an occupancy rate of 96% , making it the
hottest new biotech base in Taipei City.
Mayor
Chiang also mentioned that Merck and Thermo Fisher chose to
establish branches in Taipei in 1989 and 2012 ,
respectively. In 2023 , Merck saw the potential of Taiwan's
biopharmaceuticals and established the sixth M Lab™ Biopharmaceutical
Technology R&D and Training Cooperation Center in Asia in the Taipei
Biotech Park . It is the first technical service
laboratory in Taiwan built by an international biotech process supplier that
fully covers the biopharmaceutical process. In the future, it will support the
needs of biomedical companies at all stages from preclinical testing to
commercial production. In 2024 , Thermo Fisher has expanded
its investment in Taiwan and established its Taiwan operations headquarters and
demonstration laboratory in the Taipei Biotech Park to provide biomedical
science training and application promotion, assist the park in shared
instrument operation technology training, enhance the resilience of the
biomedical industry, and strengthen the park's R&D capabilities !
Mayor
Chiang finally expressed special thanks to Chairman Huang Maoxiong of
Biotech Development Corporation and the Biotech team led by him for their
investment and commitment to the Taipei Biotech Park and the biotech industry.
He also thanked Merck and Thermo Fisher for choosing Taipei
and investing in Taipei, and hoped that the Taipei biotech industry would
accelerate its leap to become a shining star in the global biotech
industry !